Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
about
Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitorsMammalian target of rapamycin inhibitor-associated stomatitisReconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomesSirolimus-induced interstitial lung disease following pediatric stem cell transplantation.Sirolimus in pediatric renal transplantation.Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1.Sirolimus-induced drug fever and ciclosporin-induced leukencephalopathia with seizures in one liver transplant recipientChemical genomics approach to identify genes associated with sensitivity to rapamycin in the fission yeast Schizosaccharomyces pombe.Sirolimus-related pulmonary toxicity mimicking 'asthma like' symptoms.Pulmonary complications of solid organ and hematopoietic stem cell transplantation.Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro.Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens.Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients.Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL.Icotinib combined with rapamycin in a renal transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer: A case report.Considerations in sirolimus use in the early and late post-transplant periods.Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells.Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational studyNoninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.Renal cell carcinoma: focus on safety and efficacy of temsirolimus.Common toxicities of mammalian target of rapamycin inhibitors.Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.Everolimus: preventing organ rejection in adult kidney transplant recipients.Temsirolimus: a safety and efficacy review.Proliferation signal inhibitor toxicities after thoracic transplantation.Adverse events associated with mTOR inhibitors.mTOR inhibitors and renal allograft: Yin and Yang.Pneumonitis and pulmonary fibrosis associated with breast cancer treatments.Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature.Sirolimus induced granulomatous interstitial pneumonitis.mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.Safety of mTOR inhibitors in adult solid organ transplantation.Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase.
P2860
Q26823023-DE12BFF2-AB85-4A97-A6A8-A8D70BC0BB70Q26825301-09466049-748F-4F24-A819-90569A557D9CQ28080994-1D487811-2BCD-4961-A656-4D7436144EA5Q30300759-02A31C3E-A2B7-48F7-A25C-587E86C377AEQ33397668-94ED151E-E294-41F1-99F8-8F0940FEB82BQ34452127-3942F8B4-268A-4751-9570-04D8BD92A2B9Q34606274-B9264772-D34D-48C2-83FB-C3405A903260Q35555201-20631CDC-BE23-44BC-8E90-9019DC678676Q35615854-3BEBE634-BF93-4E13-8164-91CD42641CF5Q35740698-296CF637-EC62-487D-ABA7-8DE69B709CB9Q35775057-E86199D4-DF71-4422-B471-C10A65C6962CQ35935114-80F9C223-1421-4638-99E8-95F538AD1114Q36250851-1CAD7EDC-F239-4D80-A0FE-819AC2887847Q36553511-6818E31F-C045-4CE7-BE48-9391D8711FC8Q36920433-74721CCA-22C3-4083-9B67-061F9CA21C9EQ37388707-758B48B0-624C-4A53-9C61-DAF602B6408CQ37517602-8DFF4072-EE5D-4CAA-8C31-844135CF6C6BQ37615957-A7EB8455-01D4-4334-A4C6-E20E133F8307Q37621799-A1A2FA66-081B-475E-82BA-E775425FA263Q37695529-60489EE0-30FE-4543-9735-F71FD6EA707CQ37701147-86BDF256-DF9C-4984-A54C-42E92DF5B0E6Q37828399-58B3E1EF-FECD-4F71-B1DA-45B506522D8CQ37866137-F2CB4096-4E8E-4193-A721-E990BD306719Q37873950-218FCE69-190B-4AD1-A59B-B4FB3B6CA231Q37992135-5F208F10-F2F1-424E-8D84-7AD8D4500C8DQ38031941-2131C9B8-2415-4D2D-97D1-7DDA9BBB90D1Q38044748-B226C310-9C68-42A9-ADEA-88A73D526CB9Q38068519-9C1CFD65-76D5-45CA-B8AA-1BF490BE2E43Q38209973-179DA8A2-099E-44C9-B28A-360824CE6BCDQ38220276-26E06F85-4030-43DB-9DE7-C5A25DF234AAQ38223222-A9FC4CE6-0DF6-4838-8D3A-3D2E162DAAA6Q38314899-5C9D2395-E7E7-40C0-8F27-3AC9B32EE5CBQ38510349-75D81115-1F03-48CB-9522-91705CDCC5CCQ38603164-79736088-AAFA-4000-980A-F0A856B53422Q38669190-6F528603-27CD-40AC-B954-9EEF545D1705Q38882776-B3BD6D5B-553A-43D1-A4AF-8D2F0E7E2925Q38914374-2CEA2DC8-991C-4C4A-A078-1CB19339FE1AQ38961196-C69EE556-2A9F-4B20-B0E0-63651ACD454AQ38962103-C07087B7-9018-4C0A-9D29-6A1965B47665Q39060681-03C3A178-4725-4BF7-A733-25EC8DF50EF7
P2860
Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Characteristics of sirolimus-a ...... in renal transplant patients.
@ast
Characteristics of sirolimus-a ...... in renal transplant patients.
@en
Characteristics of sirolimus-a ...... in renal transplant patients.
@nl
type
label
Characteristics of sirolimus-a ...... in renal transplant patients.
@ast
Characteristics of sirolimus-a ...... in renal transplant patients.
@en
Characteristics of sirolimus-a ...... in renal transplant patients.
@nl
prefLabel
Characteristics of sirolimus-a ...... in renal transplant patients.
@ast
Characteristics of sirolimus-a ...... in renal transplant patients.
@en
Characteristics of sirolimus-a ...... in renal transplant patients.
@nl
P2093
P1433
P1476
Characteristics of sirolimus-a ...... in renal transplant patients.
@en
P2093
Correas JM
Israël-Biet D
Peraldi MN
P304
P356
10.1097/00007890-200109150-00008
P577
2001-09-01T00:00:00Z